According to a new report, published by KBV research, The Global Obesity Intervention Devices Market size is expected to reach $352 Million by 2029, rising at a market growth of 5.3% CAGR during the forecast period.
The Clinics & Others segment is showcasing a CAGR of 7% during (2023 - 2029). A rise in the demand for non-invasive or minimally invasive treatments for obesity has sparked the growth of specialized clinics that offer weight loss programs. Because these clinics offer patients individualized treatment plans and counselling services, the segment is experiencing high demand. In addition, the use of clinics can provide patients with an alternative to hospital-based therapies that can be costly and occasionally involve long delays.
The Gastric Bands segment is leading the Global Obesity Intervention Devices Market by Device in 2022 thereby, achieving a market value of $169.2 million by 2029. Surgeons treat obesity with gastric band technology, which helps patients eat less by restricting their food intake. A smaller stomach pouch comes from placing these devices around the top portion of the stomach. Laparoscopic surgical techniques include gastric banding, one of the least intrusive procedures. High demand for laparoscopic and less invasive bariatric procedures, improved healthcare infrastructure, and rising medical tourism in developing nations are the main drivers of the growth in this segment.
The North America market dominated the Global Obesity Intervention Devices Market by Region in 2022, and would continue to be a dominant market till 2029; thereby, achieving a market value of $124.4 million by 2029. The Asia Pacific market is experiencing a CAGR of 6% during (2023 - 2029). Additionally, The Europe market would showcase a CAGR of 5.1% during (2023 - 2029).
Full Report: https://www.kbvresearch.com/obesity-intervention-devices-market/
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Johnson & Johnson, Apollo Endosurgery, Inc. (Boston Scientific Corporation), ReShape Lifesciences, Inc., AbbVie, Inc., Allurion Technologies, Inc., Spatz FGIA, Inc, Cousin Surgery, A.M.I. GmbH, ENDALIS, and GI Dynamics, Inc.
By End User
By Device
By Geography
Companies Profiled
Unique Offerings 
